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Abstract
A prothrombotic state is reported with severe COVID-19 infection, which can manifest in venous and arterial thrombotic 
events. Coagulopathy is reflective of more severe disease and anticoagulant thromboprophylaxis is recommended in hospi-
talized patients. However, the prevalence of thrombosis on the intensive care unit (ICU) remains unclear, including whether 
this is sufficiently addressed by conventional anticoagulant thromboprophylaxis. We aimed to identify the rate of thrombotic 
complications in ICU-treated patients with COVID-19, to inform recommendations for diagnosis and management. A sys-
tematic review was conducted to assess the incidence of thrombotic complications in ICU-treated patients with COVID-19. 
Observational studies and registries reporting thrombotic complications in ICU-treated patients were included. Information 
extracted included patient demographics, use of thromboprophylaxis or anticoagulation, method of identifying thrombotic 
complications, and reported patient outcomes. In 28 studies including 2928 patients, thrombotic complications occurred 
in 34% of ICU-managed patients, with deep venous thrombosis reported in 16.1% and pulmonary embolism in 12.6% of 
patients, despite anticoagulant thromboprophylaxis, and were associated with high mortality. Studies adopting systematic 
screening for venous thrombosis with Duplex ultrasound reported a significantly higher incidence of venous thrombosis 
compared to those relying on clinical suspicion (56.3% vs. 11.0%, p < 0.001). Despite thromboprophylaxis, there is a very 
high incidence of thrombotic complications in patients with COVID-19 on the ICU. Systematic screening identifies many 
thrombotic complications that would be missed by relying on clinical suspicion and should be employed, with consideration 
given to increased dose anticoagulant thromboprophylaxis, whilst awaiting results of prospective trials of anticoagulation 
in this cohort.
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Impact Despite thromboprophylaxis, there is a very high 
incidence of thrombotic complications in patients with 
COVID-19 on the ICU, affecting up to 85-92% patients. 
Systematic screening with ultrasonography identifies many 
venous thrombotic complications that could be missed by relying 
on clinical suspicion, and is recommended, with consideration of 
increased dose anticoagulatant thromboprophylaxis.
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SARS-Cov-2  Severe acute respiratory syndrome corona-
virus 2
VTE  Venous thromboembolism
Highlights
• The risk of thrombotic complications increases with the 
severity of COVID-19.
• Thromboprophylaxis is recommended for hospitalised 
patients, but the effectiveness of this, and the incidence 
of thrombotic events in patients managed in the intensive 
care unit (ICU) is unknown.
• In 28 studies assessing 2928 critically-ill patients with 
COVID-19 on the ICU, the incidence of thrombotic 
events was 34%, but studies employing systematic 
screening reported a significantly higher incidence of 
venous thrombosis compared to those relying on clini-
cal suspicion alone (56.3% vs. 11.0%, p < 0.001), despite 
anticoagulant thromboprophylaxis.
• Consideration should be given to systematic screening 
and increased dose anticoagulant thromboprophylaxis in 
patients with COVID-19 on the ICU.
Introduction
A prothrombotic state, attributable to a cytokine storm 
induced by severe acute respiratory syndrome coronavirus 
2 (SARS-Cov-2) and leading to activation of the coagula-
tion cascade, is a recognised feature of severe Coronavirus 
disease 2019 (COVID-19) infection. This can manifest in 
venous thromboembolism (VTE), arterial thrombosis and 
disseminated intravenous coagulation (DIC) and coagulopa-
thy is reflective of more severe disease and adverse progno-
sis [1]. A significant number of patients with COVID-19 
require single or multiple organ support on the Intensive 
Care Unit (ICU), estimated to be between 12 and 17% of 
patients [2–5]. with the reported mortality in these cohorts 
between 25 and 40% [2, 6].
Recent international guidelines recommend that hospi-
talized patients with COVID-19 who are immobile, have 
respiratory failure or co-morbidities, as well as those requir-
ing intensive care, should receive pharmacological prophy-
laxis against VTE, in the absence of contraindications [7–9]. 
However, studies have raised concern that despite anticoagu-
lant thromboprophylaxis, patients with COVID-19 on the 
ICU are at high risk of thromboembolic events [10]. Cur-
rently the exact prevalence of thrombosis in ICU-admitted 
patients with COVID-19 remains uncertain and in particular, 
whether this is sufficiently addressed by pharmacological 
thromboprophylaxis. Other published reviews of thrombotic 
complications associated with COVID-19, to date, have not 
specifically examined the rate of thrombotic complications 
in ICU-treated patients with COVID-19, nor the role of sys-
tematic screening for VTE in this cohort [11–17]. The aim of 
this systematic review was to identify the rate of thrombotic 
complications in patients with COVID-19 admitted to ICU 
to inform recommendations for diagnosis and management.
Methods
The present systematic review was performed in accord-
ance with the Cochrane Handbook for Systematic Reviews 
and Interventions [18], using the Preferred Reporting Items 
for Systematic Reviews and Meta-Analyses (PRISMA) 
guidelines [19], and registered in the PROSPERO database 
(CRD42020192147).
Search strategy
The Pubmed/MEDLINE database was searched on 10th 
November 2020 for articles between 1 January 2020 and 
10th November 2020 that included keywords related 
to COVID-19 (Wuhan coronavirus 2019, 2019-nCoV, 
2019nCoV, COVID-19, SARS-CoV-2), venous thrombosis, 
arterial thrombosis, stroke, myocardial infarction and mes-
enteric ischaemia (search codes are shown in Supplemen-
tary eTable 3). Two authors (W.J. and R.K.) independently 
screened articles. Reference lists of included studies, rel-
evant articles, and related systematic reviews were assessed. 
Eligible articles were reviewed in depth, and disagreements 
or queries were resolved by consensus (D.A.G., W.J., R.K.).
Study selection
We included peer-reviewed observational studies and reg-
istries, both prospective and retrospective, which reported 
on thrombotic complications in patients with COVID-19 
admitted to the ICU. Articles were only included if either 
the whole population or a subgroup of the main population 
were admitted to ICU, and the incidence of thrombosis in 
the ICU group was documented. Studies that reported on 
patients receiving extracorporeal membrane oxygenation 
(ECMO) were also included, given the specific considera-
tion needed for thrombosis in these patients. Case reports 
or series, autopsy studies, articles not available in the Eng-
lish language, papers that repeated data already included in 
prior analysis and radiology studies which only selectively 
included those patients with radiological abnormalities, were 
excluded.
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Data extraction
Full text articles of eligible studies were reviewed for data 
extraction by two authors (W.J., R.K.). Information extracted 
included patient demographics (age, gender, country of 
admitting centre, comorbidities), requirement for renal 
replacement therapy (RRT) or ECMO, thromboprophy-
laxis or anticoagulation upon admission to ICU (how many 
patients, what type and dose), method of identifying throm-
botic complications (clinical suspicion or routine screen-
ing), incidence and type of venous or arterial thrombotic 
event, dates or duration of follow-up, and reported outcomes 
(hospital/ICU length of stay, mortality). In studies where a 
subgroup of ICU patients was included, only the results from 
this subgroup were included in data extraction.
Outcome measures
The primary outcome measure was the rate of occurrence of 
arterial or venous thrombotic complications. Secondary out-
comes included the type of thrombosis including arterial or 
venous, hospital/ICU length of stay and mortality. Second-
ary analyses compared the rate of thrombotic complications 
between patients who were assessed with routine screening 
for VTE and those who were not.
Risk of bias within individual studies
The risk of bias (low, moderate, high or critical) of the 
included studies was assessed using the Cochrane Collabo-
ration tool and based on the The Risk Of Bias In Non-ran-
domized Studies of Interventions (ROBINS-I) assessment 
tool [20]. Given the limited number of publications and the 
recent interest in COVID-19, we did not assess the risk of 
publication bias as it is likely that both positive and nega-
tive findings would be published early in the course of the 
disease, although a bias in favour in publication of positive 
results cannot be excluded.
Statistical analysis
Continuous variables are presented as mean and standard 
deviation, or median and inter-quartile range (IQR) for 
normal and non-normal distributions. Dichotomous vari-
ables are presented as frequencies and percentages. The 
chi-squared test was used to assess differences. p < 0.05 
was taken as statistically significant. All analyses were per-
formed using IBM SPSS Statistics Version 26.
Results
Search results
We identified 2429 articles on direct database search, with a 
further 15 records identified through other sources (Fig. 1). 
After de-duplication, screening article titles and abstracts, 
2372 records were removed as not relevant to this review. 
The remaining 61 articles had assessment of the full text for 
eligibility. Of these, 32 were excluded; 14 due to absence of 
data on ICU patients, 6 because they only included a sub-
group of patients who had undergone CT scans, 3 because 
they only included patients who had undergone ultrasound 
doppler, 2 because they repeated data from other studies, 
2 because they were small case series, 2 that did not ade-
quately quantify thrombotic outcomes, 2 because they only 
reported outcomes on patients who had a diagnosis of pul-
monary embolism (PE) or stroke, and 1 because the article 
was not peer reviewed.
In total, 29 articles (28 studies) were included in the main 
analysis. Of these, 22 studies were specific to ICU patients, 
and 6 studies included a mixed population, with specific 
reporting on the subgroup of patients admitted to ICU. Two 
papers reported on the same patient group, with the second 
providing additional data to its predecessor [10, 21].
There was significant variation in the incidence of throm-
botic events. Few studies reported all thrombotic event types 
(some only reported one type of thrombotic event); disease 
severity differed amongst studies with 4 studies reporting 
exclusively on patients on ECMO. Importantly, some studies 
used routine screening for thrombotic complications whilst 
others did not.
Study and patient characteristics
A total of 2928 patients were included and their clinical char-
acteristics are shown in Tables 1. and 2. Where described 
(23 studies), mean patient age ranged from 45 to 70 years 
and 69% of subjects were male (24 studies). Although not 
all studies documented comorbidities, roughly a third of 
patients had diabetes, and there was a high prevalence of 
obesity, hypertension and cardiovascular disease. Nine stud-
ies documented use of ECMO. Eight studies documented 
use of RRT, which was employed in 18% of those patients.
Baseline VTE prophylaxis and anticoagulation
Twenty-four studies documented whether venous thrombo-
prophylaxis or anticoagulation was used. Twenty-one studies 
described the use of anticoagulation, 20 studies documented 
prophylactic anticoagulation, and 8 defined the anticoagulant 
dose used. There was significant variability between studies 
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on the type, dose and indication for prophylactic or thera-
peutic anticoagulation, and within some studies the throm-
boprophylaxis dosing policy changed during the analysis 
(Table 3).
Identification of thrombotic complications
Twenty-four studies described the method of identifying 
thrombotic complications. Of these, 8 studies involved sys-
tematic screening for VTE in all patients [22–29], one study 
performed selective VTE screening [30], whilst 20 studies 
did not utilise screening and relied on clinical suspicion to 
undertake tests for VTE. Two ECMO studies performed a 
thoraco-abdominopelvic CT on all new retrievals [23, 24].
The method of screening for deep venous thrombo-
sis (DVT) included Duplex ultrasound of the limbs upon 
admission to ICU [22, 25, 26, 28, 29]. In 3 studies, a repeat 
ultrasound was performed in patients without DVT on the 
first ultrasound, between 2 and 7 days after the initial scan 
[25, 26, 31].
Occurrence of thrombotic complications
All studies quantified at least one type of thrombotic com-
plication (Fig. 2 and Table 2). Thrombosis of any kind was 
reported in 996 patients (34%). Incidence of DVT was 16.1% 
(reported in 24 studies) and of PE 12.6% (22 studies). The 
incidence of arterial thrombotic events was 12% (9 studies), 
which included myocardial infarction (8%), ischaemic cer-
ebrovascular accident (3%), limb or mesenteric infarction 
(2.5%).
All studies concluded that the rate of thrombosis was 
high, and management of these patients ought to be specifi-
cally tailored to reduce thrombotic complications. Eleven 
studies suggested better risk assessment for thrombosis, with 
the use of D-dimer and improved diagnostic strategies [10, 
21, 26–28, 30, 32–36], whilst 7 suggested increasing the 
dose of anticoagulation administered, as thrombotic events 
were high despite pharmacological thromboprophylaxis [10, 
25, 26, 32, 34, 35, 37]. Some papers recommended routine 
systematic anticoagulation for all [25], while one group rec-
ommended a higher dose of thromboprophylaxis [37], which 
had already been adopted at that centre.
Fig. 1  Flowchart of literature 
review
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Routine screening vs. clinical suspicion 
to investigate thrombosis
Studies employing routine screening reported a much higher 
rate of thrombotic complications than studies without routine 
Table 1  Patient characteristics and treatments received
ECMO extracorporeal membrane oxygenation, IQR inter-quartile range, SD standard deviation
Patient demographics and treatments Mean (SD), Median (IQR) or 
patients with characteristic/total 
patients with this characteristic 
documented or n(%)
% of total patients who 
have this variable docu-
mented
Number of studies reporting on this 
demographic (Specific references in 
brackets)
Age (years) 59.9(14.1), 62(56–66), 70(62–80), 
63(53–71), 64(12), 68(51.5–74.5), 
61(16), 59(13), 61(55–69), 
62.2(8.6), 61(55–70), 65(range:32–
97), 59(49–66), 64.5(11.8), 61(14), 
62(53–69), 57(49–64), 61.7(15.8), 
45(26–66), 68(11), 59(50–61), 
50(43–62), 64(57–71)
1788/2928 (61%) 23 [10, 21–37, 39, 40, 51–53]
Male 1291/1879 (69%) 1879/2928 (64%) 24 [10, 21–33, 36, 37, 39, 40, 51–54]
Diabetes 426/1393 (31%) 1393/2928 (48%) 16 [10, 21, 22, 24, 25, 27–31, 33, 34, 
36, 37, 51–54]
Obesity 146/392 (37%) 392/2928 (14%) 3 [52, 53, 55]
Body mass index (kg/m2) 29.5(29.3–32.4), 30.2(25.5–33.5), 
34.8(11.8), 31.4(9.0), 30(26–35), 
28(24–34), 30.3(5.4), 27(24–29), 
28 (25–32), 28(25–32), 30.3(5.7), 
27.5(4.6), 27.8(25.1–33.9), 
31(27–36)
942/2928 (32%) 14 [22, 24–27, 29–31, 36, 39, 40, 52, 
54, 56, 57]
Hypertension 498/1021 (49%) 1021/2928 (35%) 13 [10, 21, 22, 25, 27, 28, 30, 31, 33, 
36, 37, 39, 52–54]
Cardiovascular disease 281/1393 (20%) 1393/2928 (48%) 15 [10, 21, 22, 25, 27–29, 31, 33, 
36–38, 51–54, 58]
Cerebrovascular disease 39/708 (6%) 708/2928 (24%) 6 [28, 36, 38, 52–54]
Atrial fibrillation 21/287 (7%) 287/2928 (10%) 3 [22, 24, 36]
Renal replacement therapy 147/834 (18%) 834/2928 (28%) 8 [10, 21, 26, 37, 38, 54–57]
ECMO 67/529 (13%) 529/2928 (18%) 9 [23, 25, 29, 36, 38–40, 57, 59]
Table 2  Incidence of thrombotic complications in the whole cohort and in patients with and without routine ultrasound screening for deep 
venous thrombosis
CVA cerebrovascular accident, DVT deep venous thrombosis, ECMO extracorporeal membrane oxygenation, MI myocardial infarction, NA not 
available, PE pulmonary embolism, RRT renal replacement therapy
Type of thrombosis Incidence of thrombotic 
complication in total 
patient cohort (n = 2929)
Incidence of event in 
patients not routinely 
screened for DVT
Incidence of event in 
patients routinely screened 
for DVT
Comparison of the incidence 
of thrombosis with screening 
vs. without screening
DVT 431/2671 (16.1%) 256/2328 (11.0%) 151/268 (56.3%) 56.3% vs. 11.0% (p < 0.001)
PE 325/2580 (12.6%) 277/2298 (12.1%) 37/207 (17.9%) 17.9% vs. 12.6% (p = 0.009)
CVA 52/1736 (3.0%) 52/1736 (3.0%) NA NA
MI 137/1736 (8.0%) 137/1736 (8.0%) NA NA
Line thrombosis 13/574 (2.3%) 13/574 (2.3%) NA NA
Limb or Mesenteric 
ischaemia
39/1566 (2.5%) 39/1566 (2.5%) NA NA
Oxygenator thrombosis 
(ECMO)
13/48 (27.1%) 13/48 (27.1%) NA NA
Circuit thrombosis (RRT) 28/29 (96.6%) 28/29 (96.6%) NA NA
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screening (Tables 2 and 3 and Fig. 2). The pooled incidence 
of DVT was 11% in studies without systematic screening, 
whereas studies employing routine screening reported a rate 
of 56.3% (p < 0.001). The incidence of PE ranged from 3 to 
35%. With the exception of two studies which only reported 
on patients on ECMO, none of the studies adopted routine 
screening for PE with CT pulmonary angiography.
Thrombotic complications of patients receiving 
ECMO
Five studies described thrombotic events in patients receiv-
ing ECMO [23, 24, 38–40]. In the one study which per-
formed screening, all 13 patients developed thromboem-
bolism during ECMO, with 85% developing DVT, 23% 
developing PE, one a thrombotic occlusion of the centrifu-
gal pump and one oxygenator thrombosis [24]. Amongst 
51 ECMO patients where screening CT was performed, the 
incidence of PE was 35% [23], whilst another study reported 
ECMO-related thrombosis in 64% of patients, a significantly 
higher prevalence than that in non-COVID-19 controls [40]. 
Another study reported a 33% rate of thrombotic complica-
tions, including 17% mortality related to thrombotic com-
plications [39].
Thrombotic complications and in‑hospital mortality
Of the 28 studies, 20 reported in-hospital mortality, rang-
ing from 9 to 54% (eTable 1). Nine studies reported on 
the differential mortality between those with and without 
thrombotic complications. One cohort study of 184 patients 
showed that patients with VTE had higher mortality than 
patients without thromboembolism [10, 21]. However, a 
subsequent larger study of 829 ICU patients showed similar 
mortality rate between those who developed any thrombotic 
event (59.8%) and those who did not (52.1%) [41]. At the 
Fig. 2  Bar chart presenting percentage of patients with throm-
botic complications by study. Panel background shows studies that 
employed routine screening for venous thrombosis (blue) and those 
that relied on clinical suspicion to investigate thrombotic complica-
tions (green). * Denotes those studies employing routine screening 
for venous thromboses. ✣ Denotes those studies employing routine 
screening for venous thromboses with computed tomography. # This 
study employed routine screening for venous thrombosis in only 51% 
of patients. † This study did not differentiate the types of arterial or 
venous thrombotic events, although reporting 7.6% venous throm-
botic events (blue) and 5.6% arterial events (red). CVA cerebrovascu-
lar accident, DVT deep vein thrombosis, ECMO extracorporeal mem-
brane oxygenator, MI myocardial infarction, PE pulmonary embolism
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point of analysis, 14 studies reported that patients remained 
in hospital, ranging from 6 to 83% of patients. Eight studies 
reported the number of patients who had been discharged 
from hospital, ranging from 0 to 79% of patients. The length 
of hospital stay and duration of follow up were only docu-
mented in a few studies (eTable 1).
Risk of bias within individual studies
The risk of bias in the included studies was assessed using 
the Cochrane Collaboration tool (eTable 4). Thirteen studies 
showed a high risk of bias, notably selection bias secondary 
to early reporting of results, without a set follow-up period. 
There is also significant reporting bias, due to limited report-
ing of all thromboembolic complications.
Discussion
This review demonstrates a very high incidence of throm-
botic complications in patients with COVID-19 admitted to 
ICU, despite anticoagulant thromboprophylaxis. Secondly, 
it is clear that thrombotic complications are frequently unde-
tected in the ICU setting, as evidenced by the very high 
incidence in studies that employed systematic screening for 
thrombotic complications, compared to those that relied on 
clinical suspicion to trigger investigation.
The rate of thrombotic complications appears signifi-
cantly higher than that seen in patients with non-COVID-19 
sepsis or pneumonia admitted to ICU. One of the studies 
included in our review compared COVID-19 patients with 
matched non-COVID-19 patients with ARDS on the ICU 
and showed a much higher rate of thrombotic complication 
with COVID-19 (11.7% vs. 4.8%) [38]. Similarly, Poissy 
et al. reported a much higher rate of thrombotic compli-
cations in patients admitted to ICU with COVID-19 than 
in ICU-admitted patients with influenza (20.6% vs 6.1%) 
[34]. A report on 198 hospitalised patients with COVID-19 
receiving thromboprophylaxis (75 of whom were treated on 
ICU), showed the incidence of thrombotic complications 
increased over time and was related to increased mortality 
[30].
Clinically, thrombotic complications are often difficult to 
recognise in intubated patients, particularly in patients with 
COVID-19, where any deterioration in lung function due 
to PE or pulmonary thrombosis may be assumed to be part 
of the clinical progression of the ARDS. Furthermore, CT 
imaging may be less frequently performed due to the chal-
lenges and risks associated with moving critically unwell 
ventilated patients to a scanner, complicated further by the 
necessity to limit intra-hospital COVID-19 transmission. 
However, the high incidence of thrombotic complications 
in studies using systematic screening implies that clinical 
suspicion alone results in significant under-detection of 
thromboembolic events on ICU. This is supported by 
autopsy studies which show high rates of thrombosis at the 
macrovascular and microvascular level [42].
A prothrombotic state is an emerging hallmark of severe 
COVID-19 and elevations in D-dimer and prothrombin time 
are well documented and related to increased mortality [43], 
with severe coagulation abnormalities reported in almost all 
patients with severe disease [44, 45]. However, measurement 
of D-dimer level is generally not helpful in predicting throm-
botic complications in ICU-treated patients, in particular 
given the significant baseline elevations in this cohort [46], 
supporting the case for systematic imaging in this cohort.
The importance of anticoagulant thromboprophylaxis in 
patients hospitalised with COVID-19 is well recognised. In 
March, the International Society on Thrombosis and Haemo-
stasis (ISTH) and the American Society of Haematology rec-
ommended that all hospitalized COVID-19 patients should 
receive prophylactic-dose low molecular weight heparin 
(LMWH) unless contraindicated [47, 48]. The American 
College of Chest Physicians (CHEST) expert panel guide-
line, published on June 2, 2020 [7] recommends standard 
dose anticoagulant thromboprophylaxis in ICU patients, 
and does not advocate addition of mechanical prophylaxis 
(i.e. intermittent pneumatic compression) to pharmacologi-
cal thromboprophylaxis. On the other hand, the latest ISTH 
consensus statement published on May 27, 2020 [8] whilst 
recommending routine thromboprophylaxis in COVID-19 
patients on the ICU with preferably standard-dose LMWH 
or unfractionated heparin, recommended that patients with 
obesity should be considered for a 50% increase in the dose 
of thromboprophylaxis and multi-modal thromboprophylaxis 
with mechanical methods should be considered. Further-
more, intermediate-dose LMWH for ICU patients was advo-
cated by up to 50% of ISTH respondents. This is supported 
by an analysis of 2,733 hospitalised patients with COVID-19 
in New York which reported that anticoagulation improved 
survival, and subgroup analysis indicated that use of treat-
ment-dose anticoagulation (received by 28% of patients) 
may be associated with improved survival compared to no-
anticoagulation or prophylactic-dose anticoagulation, par-
ticularly in patients receiving mechanical ventilation [49]. A 
retrospective evaluation of 3480 patients with COVID-19 of 
whom 18% required ICU, showed the benefit of anticoagula-
tion in reducing mortality appeared to be dose-dependent, 
with the greatest impact in those with critical illness [50].
The current anticoagulant thromboprophylaxis employed 
by the majority of studies reported here appears insufficient 
in patients with COVID-19 managed on the ICU. There 
may be a number of possible explanations for this. Firstly, 
the prothrombotic state in severe COVID-19 sepsis may be 
much more profound than previously appreciated, and more 
severe than in patients with severe sepsis of other aetiol-
ogy. Further, owing to viral adhesion occuring on the ACE2 
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receptor on endothelial cells, the degree of endothelial dys-
function through viral replication, inflammatory cell infiltra-
tion and apoptosis may be greater [46]. Secondly, because 
of the difficulty in detecting VTE on the ICU, it is possible 
that in some patients thrombotic complications developed 
before admission to ICU and perhaps even before thrombo-
prophylaxis was instituted. Thirdly, obesity is highly preva-
lent amongst this cohort and it is possible that the dose of 
thromboprophylaxis may have been insufficient for those 
with extreme BMI.
This review also highlights the high incidence of arterial 
thrombotic events, corroborated by other studies [60, 61]. 
In the setting of COVID-19, myocardial injury, defined by 
an increased troponin level, is predominantly attributable 
to non-ischaemic myocardial processes. Thus, whilst many 
early reports in patients with COVID-19 equated a troponin 
rise with myocardial infarction, typically this is more like 
to be related to sepsis and associated systemic inflammatory 
response, pro-coagulant status, and myocarditis. Without 
regular screening with cardiac biomarkers, in the absence 
of major ECG changes, myocardial injury in patients with 
COVID-19 can be frequently missed and yet is associated 
with an increased mortality [62, 63]. Likewise, stroke can be 
very challenging to recognise in patients who are intubated 
and ventilated, due to masking of clinical signs and symp-
toms with sedation and neuromuscular blockade. Unlike the 
case with the use of anticoagulation for thromboprophylaxis 
of venous thrombotic events, there are no convincing data 
that use of antiplatelet agents (or indeed anticoagulation) can 
reduce the frequency of arterial thrombotic events in patients 
with COVID-19 on the ICU.
Limitations
There is inherent bias in all observational cohort studies. 
Selection bias may favour the identification and publica-
tion of case cohorts with high rates of thrombotic compli-
cations. The retrospective nature of many studies will add 
bias. Differences between studies will add to bias, including 
variation in the ICU population studied (some including the 
highest risk patients on ECMO and RRT, others including 
lower risk patients requiring non-invasive ventilation), dif-
ferential methods of diagnosing COVID-19 (whether by 
nasopharyngeal swab or antibody testing), variation in type 
and dose of anticoagulant thromboprophylaxis and differen-
tial thresholds for investigating thrombotic complications. 
Some papers report only one type of thrombosis, whilst 
others report all available thrombosis data. Furthermore, 
differences in follow-up between studies will underestimate 
rates of thromboses, with varilable proportions of the study 
population remaining in hospital, on ICU, or even on ECMO 
at the point of publishing [39]. We compared studies that 
used systematic screening to those depending on clinical 
suspicion to diagnose thrombotic complications. In addi-
tion, differences in patient cohorts, both in terms of char-
acteristics reported (such as age, obesity, diabetes, country/
type of healthcare where study was undertaken) and those 
not reported, such as other co-morbidities, medications 
and ethnicity, the latter in particular is highly pertinent as 
black, Asian and minority ethnic (BAME) groups have been 
reported to be adversely affected by COVID-19.
Conclusion
Despite anticoagulant thromboprophylaxis, there is a very 
high incidence of thrombotic complications in patients with 
COVID-19 admitted to ICU, and systematic screening iden-
tifies many thrombotic complications that would be missed 
by relying on clinical suspicion to trigger investigation. 
Systematic screening for VTE is therefore recommended in 
this cohort, and higher dose thromboprophylaxis should be 
considered, whilst awaiting the results of prospective studies 
to guide anticoagulation in patients with severe COVID-19 
disease.
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